#ÀÎõ¼ÒȺҷ®, #ÀÎõ¼ÒȺҷ®Ä¡·á, #´ãÀûº´, #ÀÎõ´ãÀûº´, #¼ÒȺҷ®Ä¡·á, #´ãÀûº´Ä¡·á, #ÀÎõ´ãÀûº´, #ºÎõ¼ÒȺҷ®
ÀÎõ¼ÒȺҷ®,,ÀÎõ¼ÒȺҷ®Ä¡·á,,´ãÀûº´,,ÀÎõ´ãÀûº´,,¼ÒȺҷ®Ä¡·á,,´ãÀûº´Ä¡·á,,ÀÎõ´ãÀûº´,,ºÎõ¼ÒȺҷ®
¾È³çÇϼ¼¿ä. ÀÎõ¼ÒȺҷ® ºÎõ ÇÑÀÇ¿ø ãÀ¸½Ã´Â ºÐµéÀÌ ¸¹À¸½Åµ¥¿ä
ÀÎõ¼ÒȺҷ® ºÎõ Ä¡·á ãÀ¸½Ã´Â ºÐµéÀÌ ¹Ì¿ÃÇÑÀÇ¿ø ÀÎõÁ¡À» ÀÚÁÖ Ã£À¸½Ã´Âµ¥¿ä. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â´ãÀûº´, ´ãÀûÁõ, ´ãÀûº´ÇÑÀÇ¿ø, ±Þ¼ºÀå¿°, Ç÷º¯, Àå³»°¡½ºÁ¦°Å, ½Å°æ¼ºÀ§¿°, º¹ºÎ°¡½º, ½Ä¿åºÎÁø, ½Äµµ¿°, À§°æ·Ã, ¸¸¼º¼³»ç, Å©·Ðº´, À§´ãÀû, ÀæÀºÆ®¸², ´ãÀûÁõ»ó, ¸¸¼ºÀ§¿°, À§¿°¸íÄ¡, ¼Ó¿ï··°Å¸², ¸íÄ¡¾²¸², ¼ÒȺҷ®, ¼ÒȺҷ®Áö¼Ó, ÀæÀº¹èº¯, À§¼Ó¾²¸², À§ÀåÀå¾Öµî ´Ù¾çÇÑ ¹®ÀǸ¦ ÁÖ°í °è½Ê´Ï´Ù.
¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â ´Ù¾çÇÑ È¯ÀںеéÀÌ ³»¿øÇÏ°í °è½Ã¸ç °³Àκ° Áõ»ó°ú üÁú¿¡ µû¶ó °æÃßÃß³ª, Áß¼º¾îÇ÷¾àħ, mechanical therapy, ³úÇ÷·ùÃÊÀ½ÆÄ, ÁÂÈÆ¿ä¹ý, ½½¸µ¿îµ¿, ôÃß°ßÀÎÄ¡·á, ³Ã¿Â¿å, ü¿Áø´Ü(ºÎºÐ), °æÇÇ°æ±ÙÇѳÿä¹ý, Àδë°È, ¾ÆÀ̽ºÆÑ, Çѹ湰¸®Ä¡·á, ¿äõÃßÃß³ª, ¹Ì¼¼¾àÃÊÀڱؿä¹ý, ÈûÁÙ°ÈÄ¡·á, ¾È¸é°èÃø°Ë»ç, »ê»ï¾àħ, ½Å¹Ù·Î¾àħ, ·¹ÀÌÀú, ¸ÂÃãÇÑ¾à µî ÇÕ¸®ÀûÀÌ°í È¿°úÀûÀÎ ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù
¹Ì¿ÃÇÑÀÇ¿øÀº Àü±¹ 20¿©°³ ÁöÁ¡¿¡¼ Áø·áÁßÀ̸ç ÀüºÏ Á¤À¾½Ã ³ó¼Òµ¿, Á¦ÁÖ ¼±ÍÆ÷½Ã µ¿È«µ¿, °æ±â ȼº½Ã Ȳ°èµ¿, ÀüºÏ Àå¼ö±º °èºÏ¸é, Àü³² °î¼º±º ¿À°î¸é, ¿ï»ê ¿ïÁÖ±º û·®¸é, ºÎ»ê ±ÝÁ¤±¸ ºÎ°îµ¿, Àü³² ¿µ¾Ï±º »ïÈ£À¾, ÃæºÏ ¿Áõ±º ¿ÁõÀ¾, ¿ï»ê ³²±¸ °³¿îµ¿, Àü³² ¿µ±¤±º ´ë¸¶¸é, °æ³² â¿ø½Ã ¸¶»êÇÕÆ÷±¸ ¸¶»êÇÕÆ÷¿ìü±¹»ç¼ÇÔ, °¿ø °í¼º±º °ÅÁøÀ¾, ÀüºÏ ¿ÏÁÖ±º ¿îÁÖ¸é, ÀüºÏ ÀüÁֽà ´öÁø±¸ ¿ì¾Æµ¿2°¡, °¿ø Ãáõ½Ã ÈÄÆòµ¿, °æ±â ¾È¾ç½Ã ¸¸¾È±¸ ¼®¼ö2µ¿, Ãæ³² ±Ý»ê±º ±Ý»êÀ¾, °æ³² â¿ø½Ã ¼º»ê±¸ ¿ù¸²µ¿, °æ±â ¿ëÀνà ±âÈﱸ û´öµ¿, °æºÏ »óÁֽà Ȱ³µ¿, ºÎ»ê ¼ö¿µ±¸ ±¤¾Èµ¿, ÀüºÏ ±º»ê½Ã ¹ÌÀ嵿, °¿ø Æòⱺ ¹æ¸²¸é, °æ±â µ¿µÎõ½Ã »ý¿¬2µ¿, Àü³² °î¼º±º °î¼ºÀ¾, °æºÏ »óÁֽà ³»¼¸é, ºÎ»ê °¼±¸ ¹ü¹æµ¿, °æ±â ½ÃÈï½Ã Á¤¿Õ2µ¿, °æ±â ½ÃÈï½Ã Á¤¿Õ2µ¿, µî ´Ù¾çÇÑ Áö¿ª Áֹε鲲¼ ³»¿øÇÏ°í °è½Ê´Ï´Ù
ÀÎõ¼ÒȺҷ®Ä¡·á ãÀ¸½Ã´Â µ¿Ãᵿ, ¼®³²µ¿, ¼Ò·¡Æ÷±¸, ¿ëÇöµ¿, ¹è°ð½Åµµ½Ã, ÀÎõ³íÇöµ¿, ½ÃÈï, Á־ȵ¿, ¿¬¼öµ¿, ¿Á·Ãµ¿, À²¸ñµ¿, ¼±Çе¿, ³²¾çÀ¾, ÀÎõ, ±¸¿ùµ¿, ¿î¼µ¿, °£¼®µ¿, ´ëºÎµµ, ³íÇö°íÀܵ¿, Á¤¿Õµ¿, ¹è°ð, °è»êµ¿, ¼Ã¢µ¿, ¼Û¸²µ¿, ¼Ûµµ, °Ë¾Ï, °ü±³µ¿, ÀÎõÁÖ¾È, ¼Ûµµ½Åµµ½Ã, ½ÃÈ, ¼Û»ê¸é, ³²±¸, °è¾ç±¸, Áßµ¿, ¸¶µµ¸é µî ÀÎõ Áö¿ª Áֹε鲲¼ ¹Ì¿ÃÇÑÀÇ¿øÀÎõÁ¡À» ¹æ¹®ÇÏ°í °è½Ê´Ï´Ù.
´õ »ìÆ캸±â
1. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.
2. Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26:1259.
3. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86.
4. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175.
5. Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.
6. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.
7. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.
8. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30:707.
9. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15:355.
10. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473.